Johnson & Johnson (NYSE:JNJ) Shares Purchased by Defined Financial Planning LLC

Defined Financial Planning LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 10.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 2,991 shares of the company’s stock after acquiring an additional 293 shares during the period. Defined Financial Planning LLC’s holdings in Johnson & Johnson were worth $458,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. FMB Wealth Management acquired a new position in Johnson & Johnson during the first quarter worth $233,000. Yarger Wealth Strategies LLC lifted its stake in Johnson & Johnson by 6.2% during the first quarter. Yarger Wealth Strategies LLC now owns 1,560 shares of the company’s stock worth $259,000 after purchasing an additional 91 shares in the last quarter. Davis Investment Partners LLC lifted its stake in Johnson & Johnson by 7.9% during the first quarter. Davis Investment Partners LLC now owns 4,429 shares of the company’s stock worth $682,000 after purchasing an additional 326 shares in the last quarter. Net Worth Advisory Group lifted its stake in Johnson & Johnson by 5.7% during the first quarter. Net Worth Advisory Group now owns 11,200 shares of the company’s stock worth $1,857,000 after purchasing an additional 608 shares in the last quarter. Finally, ForthRight Wealth Management LLC acquired a new position in Johnson & Johnson during the first quarter worth $210,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on JNJ. Bank of America cut their price objective on Johnson & Johnson from $171.00 to $159.00 and set a “neutral” rating on the stock in a research report on Thursday, April 10th. Barclays cut their price objective on Johnson & Johnson from $166.00 to $165.00 and set an “equal weight” rating on the stock in a research report on Thursday, April 17th. Wall Street Zen lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 22nd. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a research report on Wednesday, April 2nd. Finally, Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a research report on Wednesday, April 16th. Eleven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $170.88.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $156.61 on Friday. The business’s fifty day moving average price is $153.69 and its 200 day moving average price is $153.71. The firm has a market capitalization of $376.82 billion, a PE ratio of 23.55, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.32%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 57.84%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.